<DOC>
	<DOCNO>NCT01648322</DOCNO>
	<brief_summary>This randomize open label dose find study evaluate efficacy safety F-627 woman Stage II-III breast cancer receive chemotherapy treatment .</brief_summary>
	<brief_title>Dose-Finding Trial F-627 Women With Breast Cancer Receiving Myelotoxic Chemotherapy</brief_title>
	<detailed_description>This randomize , multi-center , dose finding , open label , positive control Phase II study efficacy safety once-per-cycle F-627 compare Neulasta® ( pegfilgrastim ) woman breast cancer receive myelotoxic TC chemotherapy ( Taxotere ( docetaxel ) + cyclophosphamide ) . The primary objective study evaluate efficacy safety various single cycle dose F-627 compare standard dose Neulasta® ( pegfilgrastim ) breast cancer patient experience myelotoxic chemotherapy . Myelotoxicity study define duration moderate neutropenia ; number day patient absolute neutrophil count ( ANC ) &lt; 1.0 × 10^9/L first cycle chemotherapy treatment ( chemotherapy cycle expect last 21 day ) . This , definition , include grade 3 ( moderate ) grade 4 ( severe ) neutropenia . Doses F-627 test 80 µg/kg/dose , 240 µg/kg/dose , 320 µg/kg/dose .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Show evidence sign ( personally legally acceptable representative ) date informed consent document indicate patient inform pertinent aspect trial . Females ≥ 18 year age . Diagnosed Stage IIIII breast cancer . Subject schedule undergo 4 cycle TC TAC chemotherapy ( Taxotere® , doxorbucin cyclophosphamide , 75 , 50 600 mg/m2 , respectively ) . ECOG Performance status ≤ 2 . White Blood Cell count ( WBC ) ≥ 4.0 × 109/L , hemoglobin ≥ 11.5 g/dL platelet count ≥ 150 × 109/L . Demonstrate adequate renal , hepatic function ( Liver function test ( ALT , AST , alkaline phosphatase total bilirubin ) ) less 2.5x upper limit normal ( ULN ) . Serum creatinine le 1.7x ULN . All subject must agree use least one follow type contraception : intrauterine device , implantable progesterone device , progesterone intramuscular injection , oral contraceptive , start least one month prior visit one continue duration trial . The contraceptive patch condom use spermicide also acceptable form contraception long use continually throughout duration trial . Subject &lt; 18 ≥ 75 year age . Disease progression occur receive taxane regimen . Subject undergone radiation therapy within 4 week enrollment . Subject undergone bone marrow stemcell transplantation . Subject history prior malignancy breast cancer . Subjects use GCSF within 6 week screen period also exclude Subject chemotherapy within 365 day screen Subject document congestive heart failure , cardiomyopathy myocardial infarction clinical diagnosis , ECG test , relevant test . History alcohol drug abuse would interfere ability compliant study procedure . Unwillingness participate study . Any underlying medical condition , Investigator 's opinion , would make administration study drug hazardous patient would obscure interpretation adverse event . Receiving investigational drug biologics within 1 month five half life enrollment . Any condition , cause splenomegaly . Chronic constipation diarrhea , irritable bowel syndrome , inflammatory bowel disease . ALT , AST , alkaline phosphatase &gt; 2.5 upper limit normal . Patients active infection , know infected chronic active Hepatitis B within last 1 year ( unless show time study entry Hepatitis B antigen negative ) , history Hepatitis C. Women pregnant breastfeeding . Patients know seropositive HIV , AIDS define illness know immunodeficiency disorder . Patients history tuberculosis exposure tuberculosis . Patients receive prior chest Xray suspicion tuberculosis also exclude unless confirm PPD negative latent tuberculosis previously treat . Subjects Sickle Cell disease Subjects know hypersensitivity E.coli derive protein ' pegfilgrastim ' filgrastim , component study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Taxotere Chemotherapy</keyword>
	<keyword>Neulasta</keyword>
	<keyword>efficacy safety</keyword>
	<keyword>single cycle dose F-627</keyword>
	<keyword>pegfilgrastim</keyword>
</DOC>